Fagron (FAGR) Q3 2024 earnings summary

Executive summary

• Achieved nine-month organic revenue growth of 12.6% at constant exchange rates, with all regions and segments contributing strongly.

• Q3 2024 reported revenue grew 12.1% to €214.5 million, with organic growth at 12.2% at CER.

• North America remains the largest growth driver, with Latin America and EMEA also showing robust performance, supported by operational improvements.

• Three strategic acquisitions announced: Purifarma (Brazil), EuroOTC (Germany), and Ritedose (North America), enhancing global market leadership.

Financial highlights

• Q3 2024 revenue reached €214.5 million, up 12.1% year-over-year; nine-month 2024 revenue was €643.8 million, up 14.4% year-over-year.

• Organic revenue growth at constant exchange rates was 12.2% for Q3 and 12.6% for the nine-month period.

• Full-year revenue guidance reaffirmed at €850–€870 million, with year-on-year profitability improvement expected.

• Maintenance CapEx to remain at 3–3.5% of revenue, excluding one-off projects.

• Negative FX impact, mainly from the weaker Brazilian real, reduced Q3 revenue by approximately €5.3 million.

Outlook and guidance

• Guidance excludes Ritedose acquisition, which added €2 million in Q3 inorganic growth.

• Profitability expected to improve year-on-year, with Americas margin moving toward 21.5% and LatAm H2 margins expected to surpass H1.

• Midterm targets for sales and profitability remain, with margin improvement expected as integration and operational excellence projects progress.

• Guidance assumes stable market conditions for the remainder of the year.